Voyager Therapeutics, Inc. (VYGR) Form 8-K — Oct 21, 2026

$VYGRForm 8-KItems 5.02, 9.01Filed Oct 21, 2026, 8:07 AM ET0001193125-26-427224Original filing

Voyager Therapeutics appointed Chief Business Officer and COO Robin Swartz as President effective October 20, 2026, and she is expected to succeed Alfred W. Sandrock, Jr. as CEO following anticipated receipt of initial acute safety data for its VY1706 Alzheimer's trial in Q1 2027. Sandrock is expected to remain on the Board after the transition.

Key figures

Base salary usd: 625000
Target bonus pct: 50
Promotion rsu shares: 68250
Promotion option shares: 318500
Severance months salary: 12

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.